PURPOSE: Human troponin I (TROP), the soluble receptor for vascular endothelial growth factor (sFLT) and angiostatin (ASTAT) are potent inhibitors of endothelial cell proliferation, angiogenesis and tumour growth in vivo. Transfer of these genes into tumours may induce changes not only in perfusion, but also more general ones such as changes in metabolism. The aim of this study was to assess these reactions using FDG-PET and high-throughput methods such as gene profiling. METHODS: We established Morris hepatoma (MH3924A) cell lines expressing TROP, sFLT or ASTAT and quantified (18)F-fluorodeoxyglucose ((18)FDG) uptake by dynamic positron emission tomography (PET) after tumour inoculation in ACI rats. Furthermore, expression of glucose transporter-1 and -3 (GLUT-1 and GLUT-3) as well as hexokinase-1 and -2 were investigated by RT-PCR and immunohistomorphometry. In addition, gene array analyses were performed. RESULTS: (18)FDG uptake, vascular fraction and distribution volume were significantly higher in all genetically modified tumours. Immunohistomorphometry showed an increased percentage of hexokinase-1 and -2 as well as GLUT-1 and -3 immunoreactive (ir) cells. Using gene arrays and comparing all three groups of genetically modified tumours, we found upregulated expression of 36 genes related to apoptosis, signal transduction, stress or metabolism. CONCLUSION: TROP-, sFLT- or ASTAT-expressing MH3924A tumours show enhanced influx of (18)FDG, which seems to be caused by several factors: enhanced exchange of nutrients between blood and tumour, increased amounts of glucose transporters and hexokinases, and increased expression of genes related to apoptosis, matrix and stress, which induce an increased demand for glucose.
PURPOSE:Human troponin I (TROP), the soluble receptor for vascular endothelial growth factor (sFLT) and angiostatin (ASTAT) are potent inhibitors of endothelial cell proliferation, angiogenesis and tumour growth in vivo. Transfer of these genes into tumours may induce changes not only in perfusion, but also more general ones such as changes in metabolism. The aim of this study was to assess these reactions using FDG-PET and high-throughput methods such as gene profiling. METHODS: We established Morris hepatoma (MH3924A) cell lines expressing TROP, sFLT or ASTAT and quantified (18)F-fluorodeoxyglucose ((18)FDG) uptake by dynamic positron emission tomography (PET) after tumour inoculation in ACI rats. Furthermore, expression of glucose transporter-1 and -3 (GLUT-1 and GLUT-3) as well as hexokinase-1 and -2 were investigated by RT-PCR and immunohistomorphometry. In addition, gene array analyses were performed. RESULTS: (18)FDG uptake, vascular fraction and distribution volume were significantly higher in all genetically modified tumours. Immunohistomorphometry showed an increased percentage of hexokinase-1 and -2 as well as GLUT-1 and -3 immunoreactive (ir) cells. Using gene arrays and comparing all three groups of genetically modified tumours, we found upregulated expression of 36 genes related to apoptosis, signal transduction, stress or metabolism. CONCLUSION: TROP-, sFLT- or ASTAT-expressing MH3924A tumours show enhanced influx of (18)FDG, which seems to be caused by several factors: enhanced exchange of nutrients between blood and tumour, increased amounts of glucose transporters and hexokinases, and increased expression of genes related to apoptosis, matrix and stress, which induce an increased demand for glucose.
Authors: U Haberkorn; M E Bellemann; G Brix; H Kamencic; I Morr; U Traut; A Altmann; J Doll; J Blatter; R Kinscherf Journal: Eur J Nucl Med Date: 2001-04
Authors: U Haberkorn; S I Ziegler; F Oberdorfer; H Trojan; D Haag; P Peschke; M R Berger; A Altmann; G van Kaick Journal: Nucl Med Biol Date: 1994-08 Impact factor: 2.408
Authors: A M Al-Zoubi; E V Efimova; S Kaithamana; O Martinez; M El-A El-Idrissi; R E Dogan; B S Prabhakar Journal: J Biol Chem Date: 2001-09-27 Impact factor: 5.157
Authors: Kerstin Schmidt; Johannes Hoffend; Annette Altmann; Ludwig G Strauss; Antonia Dimitrakopoulou-Strauss; Britta Engelhardt; Dirk Koczan; Jörg Peter; Silke Vorwald; Helmut Eskerski; Michael Eisenhut; Jürgen Metz; Ralf Kinscherf; Uwe Haberkorn Journal: Clin Cancer Res Date: 2005-03-15 Impact factor: 12.531
Authors: Georgia Hatzivassiliou; Fangping Zhao; Daniel E Bauer; Charalambos Andreadis; Anthony N Shaw; Dashyant Dhanak; Sunil R Hingorani; David A Tuveson; Craig B Thompson Journal: Cancer Cell Date: 2005-10 Impact factor: 31.743
Authors: Roy S Herbst; Kenneth R Hess; Hai T Tran; Jennifer E Tseng; Nizar A Mullani; Chusilp Charnsangavej; Timothy Madden; Darren W Davis; David J McConkey; Michael S O'Reilly; Lee M Ellis; James Pluda; Waun K Hong; James L Abbruzzese Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: Guellue Cataldegirmen; Shan Zeng; Nikki Feirt; Nikalesh Ippagunta; Hao Dun; Wu Qu; Yan Lu; Ling Ling Rong; Marion A Hofmann; Thomas Kislinger; Sophia I Pachydaki; Daniel G Jenkins; Alan Weinberg; Jay Lefkowitch; Xavier Rogiers; Shi Fang Yan; Ann Marie Schmidt; Jean C Emond Journal: J Exp Med Date: 2005-02-07 Impact factor: 14.307
Authors: Paul Flechsig; Clemens Kratochwil; Arne Warth; Daniel Rath; Viktoria Eichwald; Peter E Huber; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel Journal: Mol Imaging Biol Date: 2016-04 Impact factor: 3.488
Authors: Markus Thiemann; Susanne Oertel; Volker Ehemann; Wilko Weichert; Albrecht Stenzinger; Marc Bischof; Klaus-J Weber; Ramon Lopez Perez; Uwe Haberkorn; Andreas E Kulozik; Jürgen Debus; Peter E Huber; Claudia Battmann Journal: Radiat Oncol Date: 2012-03-29 Impact factor: 3.481